Recent Updates
Recently added Catalysts
BLTE Positive Sentiment Score: 85/100

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th

Key Takeaway: Belite Bio, Inc. (NASDAQ: BLTE) will present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28, 2026. Dr. Hendrick Scholl, the Chief Medical Officer, will lead the presentation, which allows for real-time interaction with investors. This comes shortly after the company initiated a New Drug Application for its product, tinlarebant, targeting Stargardt disease, following promising results from a Phase 3 trial.

Market Sentiment Analysis

POSITIVE FACTORS

  • Belite Bio announced participation in a significant investor conference.
  • The company recently initiated a New Drug Application for tinlarebant, showing progress in its pipeline.
  • Positive results from the Phase 3 DRAGON trial underline the potential efficacy and safety of tinlarebant.

Full Press Release Details

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Hendrick Scholl, Chief Medical Officer, will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference (dbVIC) on April 28th, 2026. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors. Details of the presentation are as follows:
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Participation is free of charge.
Recent Company Highlights
Initiated rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) on April 21, 2026, following the positive Phase 3 DRAGON trial results, which demonstrated a 35.7% reduction in the growth rate of retinal lesions, as measured by retinal imaging, as well as a strong safety profile.
Completed enrollment in the Phase 2/3 DRAGON II trial of tinlarebant in STGD1.
Completed a $402 million underwritten public offering to fund commercialization of tinlarebant and pipeline expansion.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Virtual Investor Conferences
T (212) 652-5958 M (917) 847-6541

Frequently Asked Questions

When will Belite Bio present at the dbVIC?

Belite Bio will present at the dbVIC on April 28, 2026.

What is the focus of Belite Bio, Inc?

Belite Bio focuses on developing novel therapeutics for degenerative retinal diseases.

What was the outcome of the Phase 3 DRAGON trial?

The Phase 3 DRAGON trial showed a 35.7% reduction in retinal lesion growth.

Is participation in the dbVIC free?

Yes, participation in the Deutsche Bank ADR Virtual Investor Conference is free.

What was recently completed by Belite Bio?

Belite Bio completed a $402 million public offering for pipeline expansion.

Last updated: Apr 22, 2026